De Vecchi A, Scalamogna A, Pini C, Castelnovo C, Colombini M, Lepore R
Divisione di Nefrologia IRCCS Ospedale Maggiore, Italy.
Adv Perit Dial. 1991;7:240-2.
Gemfibrozil was given at a daily oral dose of 600 mg to 28 CAPD patients with serum triglyceride levels higher than 200 mg/dl, after 2 months of low fat low calorie diet. Eleven patients dropped out from the study due to spontaneous withdrawal of the drug or to intercurrent hospitalization. The 17 patients who completed the study showed a significant decrease in serum total (434.6 +/- 207.9 to 237.5 +/- 81.6 mg/dl, p 0.003), VLDL (268.8 +/- 17.8 to 109.2 +/- 66.9 mg/dl, p less than 0.005) and LDL (152.9 +/- 34.6 to 119.2 +/- 30.7 mg/dl, p = 0.004) triglyceride. Serum VLDL cholesterol increased from 108.7 +/- 54.1 to 59.9 +/- 29.0 mg/dl, p = 0.003. Serum HDL cholesterol decreased from 25.4 +/- 4.8 to 35.3 +/- 6.3 mg/dl (p less than 0.001). Apo A1 increased from 117.8 +/- 16.7 to 130.8 +/- 16.7 mg/dl (p less than 0.001) and Apo B increased from 173 +/- 26.7 to 137.8 +/- 21.9 mg/dl (p less than 0.001). No clinical or laboratory side effect was observed in the patients who completed the study. Therefore dropouts were due to the poor patients' compliance rather than to the severity of side effects.
在进行两个月的低脂低热量饮食后，对28名血清甘油三酯水平高于200mg/dl的持续性非卧床腹膜透析（CAPD）患者给予每日600mg的吉非贝齐口服剂量。11名患者因自行停药或并发住院而退出研究。完成研究的17名患者的血清总甘油三酯（从434.6±207.9降至237.5±81.6mg/dl，p=0.003）、极低密度脂蛋白（VLDL，从268.8±17.8降至109.2±66.9mg/dl，p<0.005）和低密度脂蛋白（LDL，从152.9±34.6降至119.2±30.7mg/dl，p=0.004）均显著下降。血清VLDL胆固醇从108.7±54.1升至59.9±29.0mg/dl，p=0.003。血清高密度脂蛋白（HDL）胆固醇从25.4±4.8降至35.3±6.3mg/dl（p<0.001）。载脂蛋白A1从117.8±16.7升至130.8±16.7mg/dl（p<0.001），载脂蛋白B从173±26.7降至137.8±21.9mg/dl（p<0.001）。完成研究的患者未观察到临床或实验室副作用。因此，退出研究是由于患者依从性差，而非副作用的严重程度。
